Marjolein van der Poel
A5028263697- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Acute Myeloid Leukemia Research
- Chronic Lymphocytic Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- CNS Lymphoma Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- T-cell and Retrovirus Studies
- Cancer Immunotherapy and Biomarkers
- Viral-associated cancers and disorders
- Immune Cell Function and Interaction
- Childhood Cancer Survivors' Quality of Life
- Multiple Myeloma Research and Treatments
- Chronic Myeloid Leukemia Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cancer survivorship and care
- Eosinophilic Disorders and Syndromes
- Glioma Diagnosis and Treatment
- Cancer-related cognitive impairment studies
- Biosimilars and Bioanalytical Methods
- Viral Infectious Diseases and Gene Expression in Insects
- COVID-19 Clinical Research Studies
- Cutaneous lymphoproliferative disorders research
- SARS-CoV-2 and COVID-19 Research
Maastricht University
2009-2024
Maastricht University Medical Centre
2001-2024
University Medical Center
2021-2023
The University of Texas MD Anderson Cancer Center
2023
Mayo Clinic in Florida
2022
University Hospital and Clinics
2021
Henry Ford Hospital
1981
PURPOSE Epcoritamab is a subcutaneously administered CD3xCD20 T-cell–engaging, bispecific antibody that activates T cells, directing them to kill malignant CD20 + B cells. Single-agent epcoritamab previously demonstrated potent antitumor activity in dose escalation across B-cell non-Hodgkin lymphoma subtypes. PATIENTS AND METHODS In the dose-expansion cohort of phase I/II study (ClinicalTrials.gov identifier: NCT03625037 ), adults with relapsed or refractory large and at least two prior...
Abstract The role of haploidentical hematopoietic cell transplantation (HCT) using posttransplant cyclophosphamide (PTCy) for acute lymphoblastic leukemia (ALL) is being defined. We performed a retrospective, multivariable analysis comparing outcomes HCT approaches by donor adults with ALL in remission. primary objective was to compare overall survival (OS) among HCTs PTCy and HLA-matched sibling (MSD), 8/8 unrelated (MUD), 7 /8 HLA-MUD, or umbilical cord blood (UCB) HCT. Comparing MSD HCT,...
Matched sibling donors (MSDs) are preferred for allogeneic hematopoietic cell transplantation (allo-HCT) in myelodysplastic syndrome even if they older. However, whether older MSDs or younger human leukocyte antigen-matched unrelated (MUDs) associated with better outcomes remains unclear.To investigate allo-HCT using MUDs would be improved disease-free survival and less relapse compared MSDs.This retrospective cohort study assessed data reported to the Center International Blood Marrow...
Patients aged <65 years with peripheral T-cell lymphoma (PTCL) are treated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Although the addition of etoposide (CHOEP) consolidation autologous stem cell transplantation (ASCT) preferred in some countries, randomized trials lacking. This nationwide population-based study assessed impact ASCT on overall survival (OS) among patients 18 to 64 stage II IV anaplastic large-cell (ALCL), angioimmunoblastic (AITL), or PTCL not...
Allogeneic hematopoietic cell transplantation (allo-HCT) remains the only curative treatment for myelofibrosis. However, optimal conditioning regimen either with reduced-intensity (RIC) or myeloablative (MAC) is not well known. Using Center International Blood and Marrow Transplant Research database, we identified adults aged ≥18 years myelofibrosis undergoing allo-HCT between 2008-2019 analyzed outcomes separately in RIC MAC cohorts based on regimens used. Among 872 eligible patients, 493...
Post-transplant cyclophosphamide (PTCy) has significantly increased the successful use of haploidentical donors with a relatively low incidence graft-versus-host disease (GVHD). Given its increasing use, we sought to determine risk factors for GVHD after hematopoietic cell transplantation (haplo-HCT) using PTCy. Data from Center International Blood and Marrow Transplant Research on adult patients acute myeloid leukemia, lymphoblastic myelodysplastic syndrome, or chronic leukemia who...
Post-transplantation cyclophosphamide (PTCy) has been shown to effectively control graft-versus-host disease (GvHD) in haploidentical (Haplo) transplantations. In this retrospective registry study, we compared GvHD organ distribution, severity, and outcomes patients with occurring after Haplo transplantation PTCy prophylaxis (Haplo/PTCy) versus HLA-matched unrelated donor conventional (MUD/conventional). We evaluated 2 cohorts: grade 4 acute (aGvHD) including 264 1163 recipients of MUD...
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy with poor prognosis and considered incurable conventional chemotherapy. Small observational studies reported allogeneic hematopoietic transplantation (allo-HCT) offers durable remissions in patients BPDCN. We report an analysis of BPDCN who received allo-HCT, using data to the Center for International Blood Marrow Transplant Research (CIBMTR). identified 164 from 78 centers underwent allo-HCT between 2007...
We evaluate the impact of donor types on outcomes hematopoietic cell transplantation (HCT) in myelofibrosis, using Center for International Blood and Marrow Transplant Research registry data HCTs done between 2013 2019. In all 1597 patients, use haploidentical donors increased from 3% to 19% study-eligible 1032 patients who received peripheral blood grafts chronic-phase 38% recipients HCT were non-White/Caucasian. Matched sibling (MSD)-HCTs associated with superior overall survival (OS)...
Abstract COVID-19 has been associated with high mortality in patients treated Chimeric Antigen Receptor (CAR) T-cell therapy for hematologic malignancies. Here, we investigated whether the outcome improved over time primary objective of assessing COVID-19-attributable Omicron period 2022 compared to previous years. Data this multicenter study were collected using MED-A and report forms developed by EBMT. One-hundred-eighty included analysis, 39 diagnosed 2020, 35 2021 106 2022. The median...
Cytogenetic risk stratification at diagnosis has long been one of the most useful tools to assess prognosis in acute lymphoblastic leukemia (ALL). To examine prognostic impact cytogenetic abnormalities on outcomes after allogeneic hematopoietic cell transplantation, we studied 1731 adults with Philadelphia-negative ALL complete remission who underwent myeloablative or reduced intensity/non-myeloablative conditioning transplant from unrelated matched sibling donors reported Center for...
Patients who develop therapy-related myeloid neoplasm, either myelodysplastic syndrome (t-MDS) or acute myelogenous leukemia (t-AML), have a poor prognosis. An earlier Center for International Blood and Marrow Transplant Research (CIBMTR) analysis of 868 allogeneic hematopoietic cell transplantations (allo-HCTs) performed between 1990 2004 showed 5-year overall survival (OS) disease-free (DFS) 22% 21%, respectively. Modern supportive care, graft-versus-host disease prophylaxis,...
Introduction The aim of this study was to determine the efficacy early tocilizumab treatment for hospitalized patients with COVID-19 disease. Methods Open-label randomized phase II clinical trial investigating in proven admitted general ward and need supplemental oxygen. primary endpoint 30-day mortality a prespecified 2-sided significance level α = 0.10. A post-hoc analysis performed combined mechanical ventilation or death at 30 days. Secondary objectives included comparing duration...
To develop a prognostic model for patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) myelofibrosis (MF), we examined the data of 623 allo-HCT between 2000 and 2016 in United States (the Center International Blood Marrow Transplant Research [CIBMTR] cohort). A Cox multivariable was used to identify factors mortality. weighted score using these assigned who received Europe European Bone [EBMT] cohort; n = 623). Patient age >50 years (hazard ratio [HR], 1.39; 95%...
The treatment of older, unfit patients with acute myeloid leukemia (AML) is challenging. Based on preclinical data Bruton tyrosine kinase expression/phosphorylation and ibrutinib cytotoxicity in AML blasts, we conducted a randomized phase 2 multicenter study to assess the tolerability efficacy addition 10-day decitabine (ie, Hematopoietic Cell Transplantation Comorbidity Index ≥3) higher risk myelodysplasia (HOVON135/SAKK30/15 trial). In total, 144 eligible were randomly (1:1) assigned...
7525 Background: Outcomes are poor for patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Effective treatments (tx) that drive deep, durable responses and long-term benefit needed. In the pivotal EPCORE NHL-1 trial (NCT03625037), single-agent epcoritamab (epcor) showed high complete response (CR) MRD-negativity rates, a median duration of (mDoR) not reached (NR) in pts who achieved CR, manageable safety profile as an off-the-shelf, subcutaneous (SC), CD3xCD20...
The real-world results of chimeric antigen receptor T-cell (CAR-T) therapy for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) substantially differ across countries. In the Netherlands, CAR-T tumorboard facilitates a unique nationwide infrastructure referral, eligibility assessment and data collection. aim this study was to evaluate outcomes axicabtagene ciloleucel (axi-cel) in Dutch population, including thus-far underreported effects on health-related quality life...
Abstract Patients with high-grade B-cell lymphoma MYC and BCL2 rearrangements (HGBL-MYC/BCL2) respond poorly to immunochemotherapy compared patients diffuse large not otherwise specified (DLBCL NOS) without a rearrangement. This suggests negative impact of lymphoma-intrinsic on the immune system. To investigate this, we circulating T cells natural killer (NK) HGBL-MYC/BCL2 (n = 66), DLBCL NOS 53), age-matched healthy donors (HDs; n 16) by flow cytometry performed proliferation, cytokine...
Optimal treatment in patients with refractory or relapsed peripheral T-cell lymphomas (R/R T-NHLs) is unknown. In this population-based study, outcomes R/R lymphoma not otherwise specified (PTCL NOS), angioimmunoblastic (AITL), and anaplastic kinase-positive (ALK+) ALK-negative (ALK-) large cell (ALCL) were evaluated. Patients PTCL NOS, AITL, ALK+ ALCL, ALK- ALCL (≥18 years) diagnosed 2014 to 2019 identified using the Netherlands Cancer Registry. End points overall response rate (ORR),...